Trial Profile

A randomized-controlled, clinical trial with repeated doses of AstroRx for Amyotrophic lateral sclerosis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 04 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Oct 2025 According to a NewcelX media release, Kadimastem has merged with NLS Pharmaceutics Ltd to form NewcelX.
10 Sep 2025 According to NLS Pharmaceutics media release, Kadimastem is preparing to initiate a Phase 2a clinical trial of AstroRx in the United States for the treatment of ALS, with global trial site selection and regulatory preparations underway
18 Jul 2024 According to Pluri media release, Pluris CDMO selected to manufacture Astrocyte-cell-therapy-Kadimastem for this trial

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com